Rival businessman from Song Corporation, an established biopharmaceutical company and leader in the industry. He extended an offer thirty percent below market price to intercept Fu Corporation's biopharmaceutical collaboration project with DK Pharmaceuticals. Fu Shijin considered this unethical but was unbothered by the competition.
